Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

Ceftolozane/Tazobactam

(2015) Allana J. Sucher et al.   ANNALS OF PHARMACOTHERAPY

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination

(2015) Jonathan C. Cho et al.   PHARMACOTHERAPY

β-Lactam/β-Lactamase Inhibitor Combinations

(2014) Kimberly A. Toussaint et al.   ANNALS OF PHARMACOTHERAPY

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

(2014) Myra Wooley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

(2014) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the CeftolozaneIn VivoPharmacokinetic/Pharmacodynamic Target

(2014) A. J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model

(2014) Brian D. VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

(2014) Gurudatt Chandorkar et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)

(2014) Helio S. Sader et al.   JOURNAL OF INFECTION

Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

(2014) Dilip Nathwani et al.   Antimicrobial Resistance and Infection Control

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)

(2013) David J. Farrell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model

(2013) Brian VanScoy et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Ceftolozane-Tazobactam against a Broad Spectrum of Recent Clinical Anaerobic Isolates

(2013) David R. Snydman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

2013 WSES guidelines for management of intra-abdominal infections

(2013) Massimo Sartelli et al.   World Journal of Emergency Surgery

Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities

(2012) Bartolomé Moyá et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

(2012) Benjamin Miller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

(2012) G. Chandorkar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa

(2010) B. Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions

(2010) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1

(2010) E. Riera et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Diagnosis and Management of Complicated Intra‐abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

(2009) Joseph S. Solomkin et al.   CLINICAL INFECTIOUS DISEASES